Table 1. Baseline patient demographics for four cohorts used in this study, LITHE, OSKIRA, SMC1 and SMC2.
All measurements were taken at the start of each of the clinical trials prior to treatment.
| LITHE | OSKIRA | SMC1 | SMC2 | p-value | |
|---|---|---|---|---|---|
| Cohort characteristics | |||||
| Disease Indication | RA | RA | OA | OA | - |
| N | 574 | 131 | 447 | 81 | - |
| Age (± SD) | 52.1 ± 12.3 | * | 65.7 ± 6.1 | 64.4 ± 6.38 | < 0.001 |
| % Female | 82.8 | 83.2 | 65.4 | 63.5 | 0.26 |
| BMI (mean ± SD) (n) | 27.4 ± 6.0 (567) | 27.62 ± 5.3 (131) | 28.4 ± 4.9 (447) | 28.5 ± 4.4 (81) | 0.002 |
| Burden of disease activity | - | ||||
| DAS28 | 6.5 ± 0.92 (563) | 5.7 ± 0.81 (73) | NA | NA | |
| Pain | |||||
| VAS pain | 54.4 ± 22.1 (568) | ||||
| HAQ pain | 61.3 ± 19.7 (130) | ||||
| WOMAC pain | 45.2 ± 19.3 (447) | 50.6 ± 20.5 (81) | |||
| X-ray scores | |||||
| Erosion scores | 16.8 ± 16.0 (549) | 21.9 ± 33.7 (131) | |||
| Kellgren Lawrence = 2 | 87.0% | 76.5% | |||
| Kellgren Lawrence = 3 | 13.0% | 23.5% | |||
* Ages were reported in ranges for OSKIRA: <25 (0.7%), 25–34 (6.8%), 35–44 (13.7%), 45–54 (28.1%), 55–64 (32.8%), 65–74 (16.9%) and 75–84 (0.7%)